In a preclinical study, Naumov et al. reported that EGFR-TKI resistance could be associated with VEGF elevation in both the tumor cells and host stroma and combined blockade of the VEGF receptor and EGFR pathways could abrogate both primary resistance to EGFR-TKIs and or acquired resistance due to T790M mutation [26]. Here, EGFR is linked to neoplasm.